CIK 0001427570
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Vyome Holdings, Inc
Sign in to watch- Ticker
- HIND
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 949-429-6680
- Business address
- 1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
- Former names
- ReShape Lifesciences Inc., OBALON THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-05-07 | Wood Todd Michael Vice President of Sales | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2018-04-30 | Rasdal Andrew P President & CEO | Grant or award | +2,987 | $3.27 | $10K | 457,058 |
| 2018-04-30 | Drake Neil VP Research and Development | Grant or award | +2,743 | $3.27 | $9K | 29,593 |
| 2018-04-30 | Brister Mark Chief Technology Officer | Grant or award | +2,622 | $3.27 | $9K | 166,492 |
| 2018-04-02 | MONDORE ROBERT H JR VP of Operations | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2018-03-15 | Drake Neil VP Research and Development | Purchase | +5,000 | $3.96 | $20K | 26,850 |
| 2018-03-14 | Plovanic William J. Chief Financial Officer | Purchase | +5,300 | $4.04 | $21K | 15,000 |
| 2018-03-14 | Plovanic William J. Chief Financial Officer | Purchase | +5,412 | $4.04 | $22K | 15,000 |
| 2018-03-13 | Plovanic William J. Chief Financial Officer | Purchase | +9,700 | $4.05 | $39K | 9,700 |
| 2018-03-13 | Plovanic William J. Chief Financial Officer | Purchase | +9,588 | $4.05 | $39K | 9,588 |
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise | +229 | $1.31 | $300 | 8,153 |
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise | +5,746 | $1.83 | $11K | 13,899 |
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise | +3,641 | $0.76 | $3K | 17,540 |
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise | +4,310 | $1.77 | $8K | 21,850 |
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise · Employee Stock Option (right to buy) | −229 | 0 | ||
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise · Employee Stock Option (right to buy) | −5,746 | 0 | ||
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise · Employee Stock Option (right to buy) | −3,641 | 1,083 | ||
| 2018-02-02 | Drake Neil VP Research and Development | Option exercise · Employee Stock Option (right to buy) | −4,310 | 6,034 | ||
| 2018-01-29 | VandenBerg Amy VP of Reg. and Clin. Affairs | Option exercise | +4,022 | $0.87 | $3K | 4,022 |
| 2018-01-29 | VandenBerg Amy VP of Reg. and Clin. Affairs | Option exercise | +1,087 | $0.87 | $946 | 5,109 |
Page 12 of 17 · 322 trades